公开(公告)号：US20240101687A1

公开(公告)日：2024-03-28

申请号：US18480071

申请日：2023-10-03

Applicant: ABL Bio Inc.

Inventor： Jinhyung AHN ,  Sungwon AN ,  Dongin KIM ,  Eunsil SUNG ,  Jaehyun EOM ,  Sang Hoon Lee ,  Weonkyoo YOU ,  Juhee KIM ,  Kyungjin PARK ,  Hyejin CHUNG ,  Jinwon JUNG ,  Bora LEE ,  Byungje SUNG ,  Yeunju KIM ,  Yong-Gyu SON ,  Seawon AHN ,  Daehae SONG ,  Jiseon YOO ,  Youngdon PAK ,  Donghoon YEOM ,  Yoseob LEE ,  Jaeho JUNG

IPC: C07K16/28 ,  A61K47/68 ,  C07K16/18

CPC classification number: C07K16/2863 ,  A61K47/6845 ,  C07K16/18 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/567

Abstract: The present invention relates to a bi-specific antibody that specifically binds to alpha-synuclein and IGF1R, and an use of the bi-specific antibody for the prevention, treatment and/or diagnosis of synucleinopathies associated with alpha-synuclein or alpha-synuclein aggregates, and can allow the alpha-synuclein antibody or an antigen-binding fragment thereof to penetrate the blood brain barrier to exert its action in the brain, and extend the half-life to maintain the efficacy for a long time.